|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvedBy
|
gptkb:FDA
2013
|
|
gptkbp:ATCCode
|
N06AX26
|
|
gptkbp:availableOn
|
gptkb:tablet
|
|
gptkbp:CASNumber
|
508233-74-7
|
|
gptkbp:chemicalFormula
|
C18H22N2S
|
|
gptkbp:contraindication
|
hypersensitivity to vortioxetine
|
|
gptkbp:drugClass
|
gptkb:antidepressant
serotonin modulator
|
|
gptkbp:eliminationHalfLife
|
66 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:genericName
|
gptkb:vortioxetine
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Takeda
gptkb:Lundbeck
|
|
gptkbp:mechanismOfAction
|
serotonin reuptake inhibition
serotonin receptor modulation
|
|
gptkbp:metabolism
|
liver (CYP2D6, CYP3A4, CYP2C9)
|
|
gptkbp:otherName
|
gptkb:Trintellix
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:sexual_dysfunction
nausea
vomiting
constipation
dizziness
|
|
gptkbp:usedFor
|
gptkb:major_depressive_disorder
|
|
gptkbp:bfsParent
|
gptkb:Lundbeck
gptkb:H._Lundbeck_A/S
gptkb:Vortioxetine
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Brintellix
|